CU22545A1
(es)
|
1994-11-18 |
1999-03-31 |
Centro Inmunologia Molecular |
Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
|
USRE30985E
(en)
|
1978-01-01 |
1982-06-29 |
|
Serum-free cell culture media
|
FR2413974A1
(fr)
|
1978-01-06 |
1979-08-03 |
David Bernard |
Sechoir pour feuilles imprimees par serigraphie
|
US4419446A
(en)
|
1980-12-31 |
1983-12-06 |
The United States Of America As Represented By The Department Of Health And Human Services |
Recombinant DNA process utilizing a papilloma virus DNA as a vector
|
NZ201705A
(en)
|
1981-08-31 |
1986-03-14 |
Genentech Inc |
Recombinant dna method for production of hepatitis b surface antigen in yeast
|
US4601978A
(en)
|
1982-11-24 |
1986-07-22 |
The Regents Of The University Of California |
Mammalian metallothionein promoter system
|
US4560655A
(en)
|
1982-12-16 |
1985-12-24 |
Immunex Corporation |
Serum-free cell culture medium and process for making same
|
US4657866A
(en)
|
1982-12-21 |
1987-04-14 |
Sudhir Kumar |
Serum-free, synthetic, completely chemically defined tissue culture media
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
DD266710A3
(de)
|
1983-06-06 |
1989-04-12 |
Ve Forschungszentrum Biotechnologie |
Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
|
US4767704A
(en)
|
1983-10-07 |
1988-08-30 |
Columbia University In The City Of New York |
Protein-free culture medium
|
US4943533A
(en)
|
1984-03-01 |
1990-07-24 |
The Regents Of The University Of California |
Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
|
US4965199A
(en)
|
1984-04-20 |
1990-10-23 |
Genentech, Inc. |
Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
|
US4879231A
(en)
|
1984-10-30 |
1989-11-07 |
Phillips Petroleum Company |
Transformation of yeasts of the genus pichia
|
GB8516415D0
(en)
|
1985-06-28 |
1985-07-31 |
Celltech Ltd |
Culture of animal cells
|
US4676980A
(en)
|
1985-09-23 |
1987-06-30 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Target specific cross-linked heteroantibodies
|
US6548640B1
(en)
|
1986-03-27 |
2003-04-15 |
Btg International Limited |
Altered antibodies
|
US4927762A
(en)
|
1986-04-01 |
1990-05-22 |
Cell Enterprises, Inc. |
Cell culture medium with antioxidant
|
GB8610600D0
(en)
|
1986-04-30 |
1986-06-04 |
Novo Industri As |
Transformation of trichoderma
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
EP0307434B2
(en)
|
1987-03-18 |
1998-07-29 |
Scotgen Biopharmaceuticals, Inc. |
Altered antibodies
|
DE68925971T2
(de)
|
1988-09-23 |
1996-09-05 |
Cetus Oncology Corp |
Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
KR0184860B1
(ko)
|
1988-11-11 |
1999-04-01 |
메디칼 리써어치 카운실 |
단일영역 리간드와 이를 포함하는 수용체 및 이들의 제조방법과 이용(법)
|
FR2646437B1
(fr)
|
1989-04-28 |
1991-08-30 |
Transgene Sa |
Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
|
EP0402226A1
(en)
|
1989-06-06 |
1990-12-12 |
Institut National De La Recherche Agronomique |
Transformation vectors for yeast yarrowia
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
DE69029036T2
(de)
|
1989-06-29 |
1997-05-22 |
Medarex Inc |
Bispezifische reagenzien für die aids-therapie
|
CA2066428C
(en)
|
1989-09-08 |
2000-11-28 |
Bert Vogelstein |
Structural alterations of the egf receptor gene in human gliomas
|
US5959177A
(en)
|
1989-10-27 |
1999-09-28 |
The Scripps Research Institute |
Transgenic plants expressing assembled secretory antibodies
|
US6075181A
(en)
|
1990-01-12 |
2000-06-13 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
DE69120146T2
(de)
|
1990-01-12 |
1996-12-12 |
Cell Genesys Inc |
Erzeugung xenogener antikörper
|
US6150584A
(en)
|
1990-01-12 |
2000-11-21 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
US5661016A
(en)
|
1990-08-29 |
1997-08-26 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
US5625126A
(en)
|
1990-08-29 |
1997-04-29 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
US5633425A
(en)
|
1990-08-29 |
1997-05-27 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
US5770429A
(en)
|
1990-08-29 |
1998-06-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
ES2246502T3
(es)
|
1990-08-29 |
2006-02-16 |
Genpharm International, Inc. |
Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
|
US5122469A
(en)
|
1990-10-03 |
1992-06-16 |
Genentech, Inc. |
Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
|
ES2113940T3
(es)
|
1990-12-03 |
1998-05-16 |
Genentech Inc |
Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
|
US5571894A
(en)
|
1991-02-05 |
1996-11-05 |
Ciba-Geigy Corporation |
Recombinant antibodies specific for a growth factor receptor
|
EP0586505A1
(en)
|
1991-05-14 |
1994-03-16 |
Repligen Corporation |
Heteroconjugate antibodies for treatment of hiv infection
|
ES2206447T3
(es)
|
1991-06-14 |
2004-05-16 |
Genentech, Inc. |
Anticuerpo humanizado para heregulina.
|
GB9114948D0
(en)
|
1991-07-11 |
1991-08-28 |
Pfizer Ltd |
Process for preparing sertraline intermediates
|
US7018809B1
(en)
|
1991-09-19 |
2006-03-28 |
Genentech, Inc. |
Expression of functional antibody fragments
|
US5587458A
(en)
|
1991-10-07 |
1996-12-24 |
Aronex Pharmaceuticals, Inc. |
Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
|
WO1993008829A1
(en)
|
1991-11-04 |
1993-05-13 |
The Regents Of The University Of California |
Compositions that mediate killing of hiv-infected cells
|
AU661533B2
(en)
|
1992-01-20 |
1995-07-27 |
Astrazeneca Ab |
Quinazoline derivatives
|
AU675929B2
(en)
|
1992-02-06 |
1997-02-27 |
Curis, Inc. |
Biosynthetic binding protein for cancer marker
|
ATE149570T1
(de)
|
1992-08-17 |
1997-03-15 |
Genentech Inc |
Bispezifische immunoadhesine
|
CA2149329C
(en)
|
1992-11-13 |
2008-07-15 |
Darrell R. Anderson |
Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma
|
JPH08511420A
(ja)
|
1993-06-16 |
1996-12-03 |
セルテック・セラピューテイクス・リミテッド |
抗 体
|
GB9314893D0
(en)
|
1993-07-19 |
1993-09-01 |
Zeneca Ltd |
Quinazoline derivatives
|
ATE207366T1
(de)
|
1993-12-24 |
2001-11-15 |
Merck Patent Gmbh |
Immunokonjugate
|
IL112249A
(en)
|
1994-01-25 |
2001-11-25 |
Warner Lambert Co |
Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
|
US5654307A
(en)
|
1994-01-25 |
1997-08-05 |
Warner-Lambert Company |
Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
|
IL112248A0
(en)
|
1994-01-25 |
1995-03-30 |
Warner Lambert Co |
Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
|
BR9508409A
(pt)
|
1994-07-21 |
1997-12-23 |
Akzo Nobel Nv |
Composição de peróxido transportável estável em armazenagem e uso de uma formulação de peróxido orgânico
|
US5804396A
(en)
|
1994-10-12 |
1998-09-08 |
Sugen, Inc. |
Assay for agents active in proliferative disorders
|
US5789199A
(en)
|
1994-11-03 |
1998-08-04 |
Genentech, Inc. |
Process for bacterial production of polypeptides
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
US5840523A
(en)
|
1995-03-01 |
1998-11-24 |
Genetech, Inc. |
Methods and compositions for secretion of heterologous polypeptides
|
EP2295415A1
(en)
|
1995-03-30 |
2011-03-16 |
OSI Pharmaceuticals, Inc. |
Quinazoline derivatives
|
US5641870A
(en)
|
1995-04-20 |
1997-06-24 |
Genentech, Inc. |
Low pH hydrophobic interaction chromatography for antibody purification
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
GB9508565D0
(en)
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quiazoline derivative
|
ES2304786T3
(es)
|
1995-04-27 |
2008-10-16 |
Amgen Fremont Inc. |
Anticuerpos anti-il-8 humanos, derivados a partir de xenoratones inmunizados.
|
GB9508538D0
(en)
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
EP0823941A4
(en)
|
1995-04-28 |
2001-09-19 |
Abgenix Inc |
HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
|
US5747498A
(en)
|
1996-05-28 |
1998-05-05 |
Pfizer Inc. |
Alkynyl and azido-substituted 4-anilinoquinazolines
|
CA2222231A1
(en)
|
1995-06-07 |
1996-12-19 |
Imclone Systems Incorporated |
Antibody and antibody fragments for inhibiting the growth of tumors
|
SI9620103A
(sl)
|
1995-07-06 |
1998-10-31 |
Novartis Ag |
Pirolopirimidini in postopki za njihovo pripravo
|
US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
US5760041A
(en)
|
1996-02-05 |
1998-06-02 |
American Cyanamid Company |
4-aminoquinazoline EGFR Inhibitors
|
GB9603095D0
(en)
|
1996-02-14 |
1996-04-10 |
Zeneca Ltd |
Quinazoline derivatives
|
GB9603256D0
(en)
|
1996-02-16 |
1996-04-17 |
Wellcome Found |
Antibodies
|
PL190489B1
(pl)
|
1996-04-12 |
2005-12-30 |
Warner Lambert Co |
Nieodwracalne inhibitory kinaz tyrozyny, kompozycja farmaceutyczna je zawierająca i ich zastosowanie
|
ES2186908T3
(es)
|
1996-07-13 |
2003-05-16 |
Glaxo Group Ltd |
Compuestos heterociciclos condensados como inhibidores de pproteina-tirosina-quinasas.
|
AU729039C
(en)
|
1996-08-30 |
2001-08-02 |
Upfront Chromatography A/S |
Isolation of immunoglobulins
|
ID18494A
(id)
|
1996-10-02 |
1998-04-16 |
Novartis Ag |
Turunan pirazola leburan dan proses pembuatannya
|
DK1500329T3
(da)
|
1996-12-03 |
2012-07-09 |
Amgen Fremont Inc |
Humane antistoffer, der specifikt binder TNF-alfa
|
US20080318254A9
(en)
|
1997-03-10 |
2008-12-25 |
The Regents Of The University Of California |
PSCA antibodies and hybridomas producing them
|
US6002008A
(en)
|
1997-04-03 |
1999-12-14 |
American Cyanamid Company |
Substituted 3-cyano quinolines
|
UA73073C2
(uk)
|
1997-04-03 |
2005-06-15 |
Уайт Холдінгз Корпорейшн |
Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
|
US6235883B1
(en)
|
1997-05-05 |
2001-05-22 |
Abgenix, Inc. |
Human monoclonal antibodies to epidermal growth factor receptor
|
US20020173629A1
(en)
|
1997-05-05 |
2002-11-21 |
Aya Jakobovits |
Human monoclonal antibodies to epidermal growth factor receptor
|
WO1998050038A1
(en)
|
1997-05-06 |
1998-11-12 |
American Cyanamid Company |
Use of quinazoline compounds for the treatment of polycystic kidney disease
|
US6171586B1
(en)
|
1997-06-13 |
2001-01-09 |
Genentech, Inc. |
Antibody formulation
|
DE69830315T2
(de)
|
1997-06-24 |
2006-02-02 |
Genentech Inc., San Francisco |
Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung
|
ZA986732B
(en)
|
1997-07-29 |
1999-02-02 |
Warner Lambert Co |
Irreversible inhibitiors of tyrosine kinases
|
ZA986729B
(en)
|
1997-07-29 |
1999-02-02 |
Warner Lambert Co |
Irreversible inhibitors of tyrosine kinases
|
TW436485B
(en)
|
1997-08-01 |
2001-05-28 |
American Cyanamid Co |
Substituted quinazoline derivatives
|
US6040498A
(en)
|
1998-08-11 |
2000-03-21 |
North Caroline State University |
Genetically engineered duckweed
|
ATE419009T1
(de)
|
1997-10-31 |
2009-01-15 |
Genentech Inc |
Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen
|
KR20010031813A
(ko)
|
1997-11-06 |
2001-04-16 |
윌리암 에이취 캘넌, 에곤 이 버그 |
결장 폴립 치료용 티로신 키나제 억제제로서의 퀴나졸린유도체의 용도
|
US6610833B1
(en)
|
1997-11-24 |
2003-08-26 |
The Institute For Human Genetics And Biochemistry |
Monoclonal human natural antibodies
|
ATE531812T1
(de)
|
1997-12-05 |
2011-11-15 |
Scripps Research Inst |
Humanisierung von nager-antikörpern
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
ATE375365T1
(de)
|
1998-04-02 |
2007-10-15 |
Genentech Inc |
Antikörper varianten und fragmente davon
|
AU3657899A
(en)
|
1998-04-20 |
1999-11-08 |
James E. Bailey |
Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
|
ES2188254T3
(es)
|
1998-11-19 |
2003-06-16 |
Warner Lambert Co |
N-(4-(3-chloro-4-fluoro-fenilamino)-7-(3-morfolin-4-il-propoxi)-quin azolin-6-il)-acrilamada, un inhibidor irreversible de tirosina quinasas.
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
HUP0104865A3
(en)
|
1999-01-15 |
2004-07-28 |
Genentech Inc |
Polypeptide variants with altered effector function
|
DE60039596D1
(de)
|
1999-03-30 |
2008-09-04 |
Japan Tobacco Inc |
Verfahren zur herstellung von monoklonalen antikörpern
|
EP2275540B1
(en)
|
1999-04-09 |
2016-03-23 |
Kyowa Hakko Kirin Co., Ltd. |
Method for controlling the activity of immunologically functional molecule
|
US7125978B1
(en)
|
1999-10-04 |
2006-10-24 |
Medicago Inc. |
Promoter for regulating expression of foreign genes
|
AU782626B2
(en)
|
1999-10-04 |
2005-08-18 |
Medicago Inc. |
Method for regulating transcription of foreign genes
|
EP1229125A4
(en)
|
1999-10-19 |
2005-06-01 |
Kyowa Hakko Kogyo Kk |
PROCESS FOR PRODUCING A POLYPEPTIDE
|
AU784983B2
(en)
|
1999-12-15 |
2006-08-17 |
Genentech Inc. |
Shotgun scanning, a combinatorial method for mapping functional protein epitopes
|
US6946292B2
(en)
|
2000-10-06 |
2005-09-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells producing antibody compositions with increased antibody dependent cytotoxic activity
|
US7064191B2
(en)
|
2000-10-06 |
2006-06-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Process for purifying antibody
|
CA2424602C
(en)
|
2000-10-06 |
2012-09-18 |
Kyowa Hakko Kogyo Co., Ltd. |
Antibody composition-producing cell
|
US6596541B2
(en)
|
2000-10-31 |
2003-07-22 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
JP3523245B1
(ja)
|
2000-11-30 |
2004-04-26 |
メダレックス,インコーポレーテッド |
ヒト抗体作製用トランスジェニック染色体導入齧歯動物
|
WO2002092017A2
(en)
|
2001-05-16 |
2002-11-21 |
Albert Einstein College Of Medicine Of Yeshiva University |
Human antipneumococcal antibodies from non-human animals
|
NZ592087A
(en)
|
2001-08-03 |
2012-11-30 |
Roche Glycart Ag |
Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
|
JP4359503B2
(ja)
|
2001-08-23 |
2009-11-04 |
ゲンマブ エー/エス |
インターロイキン15(il−15)に特異的なヒト抗体
|
ES2326964T3
(es)
|
2001-10-25 |
2009-10-22 |
Genentech, Inc. |
Composiciones de glicoproteina.
|
US20040093621A1
(en)
|
2001-12-25 |
2004-05-13 |
Kyowa Hakko Kogyo Co., Ltd |
Antibody composition which specifically binds to CD20
|
ATE503829T1
(de)
|
2002-04-09 |
2011-04-15 |
Kyowa Hakko Kirin Co Ltd |
Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins
|
US20040110704A1
(en)
|
2002-04-09 |
2004-06-10 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells of which genome is modified
|
CA2481837A1
(en)
|
2002-04-09 |
2003-10-16 |
Kyowa Hakko Kogyo Co., Ltd. |
Production process for antibody composition
|
AU2003236019A1
(en)
|
2002-04-09 |
2003-10-20 |
Kyowa Hakko Kirin Co., Ltd. |
Drug containing antibody composition appropriate for patient suffering from Fc Gamma RIIIa polymorphism
|
AU2003236018A1
(en)
|
2002-04-09 |
2003-10-20 |
Kyowa Hakko Kirin Co., Ltd. |
METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa
|
US7691568B2
(en)
|
2002-04-09 |
2010-04-06 |
Kyowa Hakko Kirin Co., Ltd |
Antibody composition-containing medicament
|
EP1513879B1
(en)
|
2002-06-03 |
2018-08-22 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
US20040033228A1
(en)
|
2002-08-16 |
2004-02-19 |
Hans-Juergen Krause |
Formulation of human antibodies for treating TNF-alpha associated disorders
|
US7361740B2
(en)
|
2002-10-15 |
2008-04-22 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
DE60332957D1
(de)
|
2002-12-16 |
2010-07-22 |
Genentech Inc |
Immunoglobulinvarianten und deren verwendungen
|
AU2004205631A1
(en)
|
2003-01-16 |
2004-08-05 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
CA2513308A1
(en)
|
2003-01-17 |
2004-08-05 |
Josef Michl |
Pancreatic cancer associated antigen, antibody thereto, and diagnostic and treatment methods
|
US20060276527A1
(en)
|
2003-01-17 |
2006-12-07 |
Thresold Pharmaceuticals, Inc. |
Combination therapies for the treatment of cancer
|
US20060104968A1
(en)
|
2003-03-05 |
2006-05-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
|
US7871607B2
(en)
|
2003-03-05 |
2011-01-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
|
AU2004270103B2
(en)
|
2003-05-21 |
2012-02-23 |
E. R. Squibb & Sons, L.L.C. |
Human monoclonal antibodies against Bacillusanthracis protective antigen
|
US7635472B2
(en)
|
2003-05-31 |
2009-12-22 |
Micromet Ag |
Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders
|
US20080241884A1
(en)
|
2003-10-08 |
2008-10-02 |
Kenya Shitara |
Fused Protein Composition
|
AU2004280065A1
(en)
|
2003-10-09 |
2005-04-21 |
Kyowa Hakko Kirin Co., Ltd. |
Process for producing antibody composition by using RNA inhibiting the function of alpha1,6-fucosyltransferase
|
EA036531B1
(ru)
|
2003-11-05 |
2020-11-19 |
Роше Гликарт Аг |
Гуманизированное антитело типа ii к cd20 (варианты), фармацевтическая композиция, содержащая эти варианты антитела, и их применение
|
DK1691833T3
(da)
|
2003-11-28 |
2010-05-03 |
Micromet Ag |
Præparater der omfatter polypeptider
|
JPWO2005053742A1
(ja)
|
2003-12-04 |
2007-06-28 |
協和醗酵工業株式会社 |
抗体組成物を含有する医薬
|
US7235641B2
(en)
|
2003-12-22 |
2007-06-26 |
Micromet Ag |
Bispecific antibodies
|
MXPA06011199A
(es)
|
2004-03-31 |
2007-04-16 |
Genentech Inc |
Anticuerpos anti-tgf-beta humanizados.
|
US7785903B2
(en)
|
2004-04-09 |
2010-08-31 |
Genentech, Inc. |
Variable domain library and uses
|
CA2885854C
(en)
|
2004-04-13 |
2017-02-21 |
F. Hoffmann-La Roche Ag |
Anti-p-selectin antibodies
|
TWI380996B
(zh)
|
2004-09-17 |
2013-01-01 |
Hoffmann La Roche |
抗ox40l抗體
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
LT2439273T
(lt)
|
2005-05-09 |
2019-05-10 |
Ono Pharmaceutical Co., Ltd. |
Žmogaus monokloniniai antikūnai prieš programuotos mirties 1(pd-1) baltymą, ir vėžio gydymo būdai, naudojant vien tik anti-pd-1 antikūnus arba derinyje su kitais imunoterapiniais vaistais
|
CN105330741B
(zh)
|
2005-07-01 |
2023-01-31 |
E.R.施贵宝&圣斯有限责任公司 |
抗程序性死亡配体1(pd-l1)的人单克隆抗体
|
AU2006301492B2
(en)
|
2005-10-11 |
2011-06-09 |
Amgen Research (Munich) Gmbh |
Compositions comprising cross-species-specific antibodies and uses thereof
|
ES2577292T3
(es)
|
2005-11-07 |
2016-07-14 |
Genentech, Inc. |
Polipéptidos de unión con secuencias hipervariables de VH/VL diversificadas y consenso
|
US20070237764A1
(en)
|
2005-12-02 |
2007-10-11 |
Genentech, Inc. |
Binding polypeptides with restricted diversity sequences
|
CA2651567A1
(en)
|
2006-05-09 |
2007-11-22 |
Genentech, Inc. |
Binding polypeptides with optimized scaffolds
|
EP2061504A4
(en)
|
2006-09-20 |
2010-01-27 |
Univ Johns Hopkins |
COMBINATION THERAPY FOR CANCER AND INFECTION DISEASES WITH ANTI-B7-H1 ANTIBODIES
|
US20080226635A1
(en)
|
2006-12-22 |
2008-09-18 |
Hans Koll |
Antibodies against insulin-like growth factor I receptor and uses thereof
|
LT2520590T
(lt)
|
2007-04-03 |
2018-09-10 |
Amgen Research (Munich) Gmbh |
Susijusioms rūšims specifinis rišantis domenas
|
CN100592373C
(zh)
|
2007-05-25 |
2010-02-24 |
群康科技(深圳)有限公司 |
液晶显示面板驱动装置及其驱动方法
|
US20100285039A1
(en)
|
2008-01-03 |
2010-11-11 |
The Johns Hopkins University |
B7-H1 (CD274) Antagonists Induce Apoptosis of Tumor Cells
|
BRPI0907718A2
(pt)
|
2008-02-11 |
2017-06-13 |
Curetech Ltd |
método para tratar um tumor, método para melhorar a tolerabilidade a pelo menos um agente quimiterápico, método para aumentar a sobrevida de um indivíduo que tem um tumor, método para reduzir ou prevenir recidiva tumoral, uso de um anticorpo monoclonal humanizado ou seu fragmento e anticorpo monoclonal humanizado ou seu fragmento
|
EP2262837A4
(en)
|
2008-03-12 |
2011-04-06 |
Merck Sharp & Dohme |
PD-1 BINDING PROTEINS
|
US20110159023A1
(en)
|
2008-08-25 |
2011-06-30 |
Solomon Langermann |
Pd-1 antagonists and methods for treating infectious disease
|
SI2376535T1
(sl)
|
2008-12-09 |
2017-07-31 |
F. Hoffmann-La Roche Ag |
Protitelesa anti-pd-l1 in njihova uporaba za izboljšanje funkcije celic t
|
NZ599405A
(en)
|
2009-11-24 |
2014-09-26 |
Medimmune Ltd |
Targeted binding agents against b7-h1
|
JP2013512251A
(ja)
|
2009-11-24 |
2013-04-11 |
アンプリミューン、インコーポレーテッド |
Pd−l1/pd−l2の同時阻害
|
AU2011205343B2
(en)
|
2010-01-12 |
2015-08-13 |
Nestec S.A. |
Methods for predicting response of triple-negative breast cancer to therapy
|
MA34014B1
(fr)
|
2010-01-27 |
2013-02-01 |
Takeda Pharmaceutical |
Composés permettant de réprimer un trouble nerveux périphérique induit par un agent anticancéreux
|
WO2011146382A1
(en)
|
2010-05-17 |
2011-11-24 |
Bristol-Myers Squibb Company |
Improved immunotherapeutic dosing regimens and combinations thereof
|
TW201840336A
(zh)
*
|
2011-08-01 |
2018-11-16 |
美商建南德克公司 |
利用pd-1軸結合拮抗劑及mek抑制劑治療癌症之方法
|
DK2766040T3
(da)
*
|
2011-10-14 |
2019-07-22 |
Hoffmann La Roche |
Pertuzumab, trastuzumab, docetaxel og carboplatin til behandling af brystkræft i et tidligt stadie
|
KR101981873B1
(ko)
|
2011-11-28 |
2019-05-23 |
메르크 파텐트 게엠베하 |
항-pd-l1 항체 및 그의 용도
|
US9856320B2
(en)
|
2012-05-15 |
2018-01-02 |
Bristol-Myers Squibb Company |
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
|
BR112014028396A2
(pt)
|
2012-05-15 |
2018-05-29 |
Diatech Oncology |
processo de isolamento/purificação de célula de tumor e métodos para uso da mesma
|
AU2013267161A1
(en)
|
2012-05-31 |
2014-11-20 |
Sorrento Therapeutics, Inc. |
Antigen binding proteins that bind PD-L1
|
US9682143B2
(en)
|
2012-08-14 |
2017-06-20 |
Ibc Pharmaceuticals, Inc. |
Combination therapy for inducing immune response to disease
|
US9149455B2
(en)
|
2012-11-09 |
2015-10-06 |
Abraxis Bioscience, Llc |
Methods of treating melanoma
|
MX363188B
(es)
|
2012-11-30 |
2019-03-13 |
Hoffmann La Roche |
Identificación de pacientes con necesidad de coterapia del inhibidor de pd-l1.
|
ES2721168T3
(es)
|
2013-01-11 |
2019-07-29 |
Dingfu Biotarget Co Ltd |
Agentes para tratar tumores, uso y método de los mismos
|
AR095363A1
(es)
|
2013-03-15 |
2015-10-14 |
Genentech Inc |
Biomarcadores y métodos para el tratamiento de condiciones relacionadas con pd-1 y pd-l1
|
EP2972373B1
(en)
|
2013-03-15 |
2019-10-09 |
F.Hoffmann-La Roche Ag |
Biomarkers and methods of treating pd-1 and pd-l1 related conditions
|
TN2015000444A1
(en)
|
2013-06-03 |
2017-04-06 |
Novartis Ag |
Combinations of an anti-pd-l1 antibody and a mek inhibitor and/or a braf inhibitor
|
AR097306A1
(es)
|
2013-08-20 |
2016-03-02 |
Merck Sharp & Dohme |
Modulación de la inmunidad tumoral
|
EP3791862A1
(en)
|
2013-09-11 |
2021-03-17 |
Eagle Biologics, Inc. |
Liquid protein formulations containing viscosity-lowering agents
|
AR097584A1
(es)
|
2013-09-12 |
2016-03-23 |
Hoffmann La Roche |
Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
|
BR112016009200A8
(pt)
|
2013-10-25 |
2020-03-24 |
Pharmacyclics Llc |
uso de um inibidor de btk e um inibidor imune do ponto de verificação
|
EP3060581A4
(en)
*
|
2013-10-25 |
2017-06-07 |
Dana-Farber Cancer Institute, Inc. |
Anti-pd-l1 monoclonal antibodies and fragments thereof
|
EP3083692B1
(en)
|
2013-12-17 |
2020-02-19 |
F.Hoffmann-La Roche Ag |
Methods of treating her2-positive cancers using pd-1 axis binding antagonists and anti-her2 antibodies
|
BR112016026559A8
(pt)
|
2014-05-15 |
2021-07-13 |
Bristol Myers Squibb Co |
uso de um anticorpo anti-pd-1 e outro agente anticâncer em combinação com quimioterapia dupla com base em platina (pt-dc) e kit
|
EP3166974A1
(en)
|
2014-07-11 |
2017-05-17 |
Genentech, Inc. |
Anti-pd-l1 antibodies and diagnostic uses thereof
|
MX2017016353A
(es)
|
2015-06-17 |
2018-05-02 |
Genentech Inc |
Metodos para tratar canceres de mama metastasicos o localmente avanzados con antagonistas de union al eje de pd-1 y taxanos.
|
US20180353602A1
(en)
|
2015-06-29 |
2018-12-13 |
Syndax Pharmaceuticals, Inc. |
Combination of hdac inhibitor and anti-pd-l1 antibody for treatment of cancer
|
MX2019003603A
(es)
|
2016-09-29 |
2019-08-01 |
Genentech Inc |
Terapia de combinacion con un inhibidor de mek, un inhibidor del eje pd-1 y un taxano.
|